Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
151 hedge funds and large institutions have $1.83B invested in Mersana Therapeutics in 2020 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 54 increasing their positions, 45 reducing their positions, and 18 closing their positions.
129% more call options, than puts
Call options by funds: $12.1M | Put options by funds: $5.27M
89% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 18
43% more capital invested
Capital invested by funds: $1.28B → $1.83B (+$555M)
20% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 45
12% more funds holding
Funds holding: 135 → 151 (+16)
0.01% more ownership
Funds ownership: 4.02% → 4.03% (+0.01%)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$42.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$34.2M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$32.8M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$19.2M |
| 5 |
BlackRock
New York
|
+$16.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$111M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$46M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$14.2M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$14.1M |
| 5 |
O
OrbiMed
New York
|
-$12.4M |
MRSN Hedge Fund Activity: Q4 2020 in Review
151 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q4 2020, worth a combined $1.83B — up 43% from $1.28B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new MRSN positions and 18 closed out — a net gain of 16 holders — while 54 added to existing stakes and 45 trimmed.
The largest buyer was Bellevue Group, opening a new position worth an estimated $42.8M. The largest seller was NEA Management Company, exiting entirely with an estimated $111M sold.
- 151 institutional investors held Mersana Therapeutics (MRSN) as of Q4 2020, up from 135 in Q3 2020.
- Funds reported $1.83B of Mersana Therapeutics stock for Q4 2020, up 43% quarter-over-quarter.
- 34 funds opened new Mersana Therapeutics positions in Q4 2020 and 18 closed out, a net change of +16 holders.
- The largest Mersana Therapeutics buyer in Q4 2020 was Bellevue Group, an estimated $42.8M added.
- The largest Mersana Therapeutics seller in Q4 2020 was NEA Management Company, an estimated $111M sold.
Based on aggregated 13F filings for Q4 2020.